Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.

Share:

Facebook
Twitter
Pinterest
LinkedIn

Leave a Reply

Related Posts

Must-Have Lifestyle Items in 2024

As we embrace 2024, staying ahead of the curve in lifestyle trends is key to enhancing our day-to-day living. From tech gadgets to home essentials,

Top 5 Investment Ideas for 2024

As we step into 2024, the investment landscape offers a mix of challenges and opportunities. With careful planning and strategic thinking, you can position your